domperidone has been researched along with Parkinson Disease in 74 studies
Domperidone: A specific blocker of dopamine receptors. It speeds gastrointestinal peristalsis, causes prolactin release, and is used as antiemetic and tool in the study of dopaminergic mechanisms.
domperidone : 1-[3-(Piperidin-1-yl)propyl]-1,3-dihydro-2H-benzimidazol-2-one in which the 4-position of the piperidine ring is substituted by a 5-chloro-1,3-dihydro-2H-benzimidazol-2-on-1-yl group. A dopamine antagonist, it is used as an antiemetic for the short-term treatment of nausea and vomiting, and to control gastrointestinal effects of dopaminergic drugs given in the management of parkinsonism. The free base is used in oral suspensions, while the maleate salt is used in tablet preparations.
Parkinson Disease: A progressive, degenerative neurologic disease characterized by a TREMOR that is maximal at rest, retropulsion (i.e. a tendency to fall backwards), rigidity, stooped posture, slowness of voluntary movements, and a masklike facial expression. Pathologic features include loss of melanin containing neurons in the substantia nigra and other pigmented nuclei of the brainstem. LEWY BODIES are present in the substantia nigra and locus coeruleus but may also be found in a related condition (LEWY BODY DISEASE, DIFFUSE) characterized by dementia in combination with varying degrees of parkinsonism. (Adams et al., Principles of Neurology, 6th ed, p1059, pp1067-75)
| Excerpt | Relevance | Reference |
|---|---|---|
| "In a single-blind trial of therapy in 20 patients with idiopathic Parkinson disease, domperidone prevented nausea and vomiting induced by bromocriptine without diminishing beneficial central effects." | 9.05 | Bromocriptine and domperidone in the treatment of Parkinson disease. ( Agid, Y; Illas, A; Lhermitte, F; Quinn, N, 1981) |
| "From two Parkinson's disease cohorts, we assessed restless legs prevalence according to standard criteria, in patients taking vs." | 5.39 | Restless legs syndrome outside the blood-brain barrier--exacerbation by domperidone in Parkinson's disease. ( Bayard, S; Carlander, B; Cochen De Cock, V; Dauvilliers, Y; Galatas, C; Postuma, RB; Rios Romenets, S; Wolfson, C, 2013) |
| "Bromocriptine may be useful in the treatment of hypertension in patients with Parkinson's disease." | 5.27 | Parkinson's disease and hypertension: chronic bromocriptine treatment. ( Chamontin, B; Montastruc, JL; Rascol, A, 1985) |
| " The included RCTs were small (total of 28 participants in RCTs), short term (two to three weeks), only examined fludrocortisone for orthostatic hypotension in people with two conditions (diabetes and Parkinson disease), and had variable risk of bias (two had unclear risk of bias and one had low risk of bias)." | 5.12 | Fludrocortisone for orthostatic hypotension. ( Ansari, Y; Chung, KA; Gibbons, CH; Helfand, M; Peterson, K; Raj, SR; Veazie, S, 2021) |
| " During 5 days prior to the apomorphine all received Motilium (domperidone, 60 mg/d) to prevent nausea and vomiting." | 5.09 | [Apomorphine for treatment of "off-periods" in Parkinson's disease]. ( Kuritzky, A; Melamed, E; Merims, D; Ziv, I; Zoldan, J, 1999) |
| "In a single-blind trial of therapy in 20 patients with idiopathic Parkinson disease, domperidone prevented nausea and vomiting induced by bromocriptine without diminishing beneficial central effects." | 5.05 | Bromocriptine and domperidone in the treatment of Parkinson disease. ( Agid, Y; Illas, A; Lhermitte, F; Quinn, N, 1981) |
| "A search of two bibliographic databases, the European Medicines Agency (EMA) website, Micromedex, Lexicomp and reference texts was undertaken for domperidone related reports of QT prolongation, cardiac arrhythmias and/or SCD." | 4.91 | Domperidone safety: a mini-review of the science of QT prolongation and clinical implications of recent global regulatory recommendations. ( Buffery, PJ; Strother, RM, 2015) |
| "To review the pharmacology, pharmacokinetics, efficacy, and safety of domperidone in the treatment of gastrointestinal motility disorders and emesis." | 4.80 | Domperidone: a peripherally acting dopamine2-receptor antagonist. ( Barone, JA, 1999) |
| "Domperidone is a dopamine antagonist that has recently been released in Canada." | 3.76 | Domperidone, a new dopamine antagonist. ( Champion, MC; Hartnett, M; Yen, M, 1986) |
| " We studied the effects of apomorphine (in combination with domperidone) on buccolinguofacial motoricity and on various swallowing stages by using videofluoroscopy in eight patients with dysphagia." | 3.69 | Effects of central dopaminergic stimulation by apomorphine on swallowing disorders in Parkinson's disease. ( Barat, M; Fouillet, N; Guatterie, M; Henry, P; Lozano, V; Tison, F; Wiart, L, 1996) |
| "There is limited evidence for the treatment of orthostatic hypotension in idiopathic Parkinson's disease." | 2.73 | Nonpharmacological treatment, fludrocortisone, and domperidone for orthostatic hypotension in Parkinson's disease. ( Henderson, RD; O'Maley, K; O'Sullivan, JD; Schoffer, KL, 2007) |
| " The off-awake daily duration and the levodopa dosage were significantly reduced in the patients infused with apomorphine." | 2.71 | Continuous apomorphine infusion (CAI) and neuropsychiatric disorders in patients with advanced Parkinson's disease: a follow-up of two years. ( Antonini, A; Basile, G; Di Rosa, AE; Di Rosa, E; Epifanio, A; La Spina, P; Marconi, R; Martino, G; Morgante, L; Nicita-Mauro, V; Spina, E; Stocchi, F, 2004) |
| "Eight patients with Parkinson's disease received 4- to 6-h infusions of apomorphine at low, medium, and high rates on consecutive days." | 2.68 | Apomorphine tolerance in Parkinson's disease: lack of a dose effect. ( Gancher, ST; Nutt, JG; Woodward, WR, 1996) |
| "Patients' global assessment of Parkinson's disease remained stable or improved." | 2.68 | Effect of chronic oral domperidone therapy on gastrointestinal symptoms and gastric emptying in patients with Parkinson's disease. ( McCallum, RW; Sarosiek, I; Shifflett, J; Soykan, I; Wooten, GF, 1997) |
| "Five patients with idiopathic Parkinson's disease and "end of dose deterioration" entered and completed the study." | 2.67 | Sublingual apomorphine solution in Parkinson's disease. ( Graham, SJ; Higgins, BM; Morris, JG; Panegyres, PK; Williams, BK, 1991) |
| "Domperidone is a proposed treatment of orthostatic hypotension (OH) in Parkinson's disease (PD)." | 2.55 | Domperidone for Hypotension in Parkinson's Disease: A Systematic Review. ( Bacchi, S; Chim, I; Kramer, P; Postuma, RB, 2017) |
| " We propose an alternative apomorphine challenge test, with a single injection and a higher initial dosage of 2-4 mg, as well as to schedule treatment according to the obtained response at that dosage." | 2.48 | [Proposed alternative to standard apomorphine challenge test]. ( Burguera, JA; Martínez-Castrillo, JC, 2012) |
| "In patients with Parkinson's disease the beneficial effects of piribedil may be limited by nausea and drowsiness." | 2.38 | Parkinson's disease: pathological mechanisms and actions of piribedil. ( Jenner, P, 1992) |
| "Domperidone treatment in intact animals evoked a significant increase in normoxic tidal volume, while haloperidol potentiated tidal volume increase in response to hypoxia." | 1.43 | Hypoxic ventilatory response after dopamine D2 receptor blockade in unilateral rat model of Parkinson's disease. ( Andrzejewski, K; Budzińska, K; Kaczyńska, K; Zaremba, M, 2016) |
| "Domperidone use may increase the risk of VT/SCD in patients with PD, particularly those with a history of cardiovascular disease." | 1.43 | Ventricular tachyarrhythmia and sudden cardiac death with domperidone use in Parkinson's disease. ( Blais, L; Bugden, S; Dell'Aniello, S; Dormuth, C; Ernst, P; Evans, C; Khairy, P; Marras, C; Renoux, C; Steele, R; Tamim, H; Turin, TC, 2016) |
| "From two Parkinson's disease cohorts, we assessed restless legs prevalence according to standard criteria, in patients taking vs." | 1.39 | Restless legs syndrome outside the blood-brain barrier--exacerbation by domperidone in Parkinson's disease. ( Bayard, S; Carlander, B; Cochen De Cock, V; Dauvilliers, Y; Galatas, C; Postuma, RB; Rios Romenets, S; Wolfson, C, 2013) |
| "Apomorphine is a potent short-acting D1/D2 dopamine agonist administered sub-cutaneously that is used in the treatment of PD." | 1.35 | The pragmatic use of apomorphine at the end of life. ( Dewhurst, F; Lee, M; Wood, B, 2009) |
| "In the treatment of Parkinson's disease, levodopa, DCI, MAO-B inhibitor, COMT inhibitors, dopamine receptor agonists, amantadine, anticholinergics have been applied and new drugs are being developed." | 1.33 | [Inter- and intraindividual pharmacokinetic variations in the treatment of Parkinson's disease]. ( Moritoyo, H; Moritoyo, T; Nagai, M; Nakatsuka, A; Nisikawa, N; Nomoto, M; Yabe, H, 2005) |
| "Apomorphine treated patients who were receiving long-term domperidone had similar abnormalities of cardiovascular reflexes to those who had been able to withdraw it." | 1.28 | Cardiovascular reflexes in Parkinson's disease: effect of domperidone and apomorphine. ( Bishop, S; Lees, AJ; Merello, M; Pirtosek, Z, 1992) |
| "Neurogenic bladder frequently occurs in Parkinson's disease." | 1.28 | [Effect of apomorphine on the bladder of parkinsonian patients]. ( Adba, MA; Aranda, B; Cramer, P, 1992) |
| "In 6 hypertensive patients with Parkinson's disease, chronic treatment with bromocriptine (46." | 1.27 | [How do we explain the antihypertensive effect of bromocriptine? Clinical and experimental contribution]. ( Chamontin, B; Montastruc, JL; Rascol, A, 1984) |
| "Domperidone pretreatment (10, 20, 40 mg, p." | 1.27 | Domperidone and levodopa in Parkinson's disease. ( Davies, CL; Dolan, AL; Finnerty, GT; Parkes, JD; Shindler, JS; Towlson, K, 1984) |
| " The dosage of L-dopa infusion ranged between 360-1,250 mg for 12 hours." | 1.27 | Problems in daily motor performances in Parkinson's disease: the continuous dopaminergic stimulation. ( Agnoli, A; Brughitta, G; Ruggieri, S; Stocchi, F, 1986) |
| " Of the 10 patients who received pergolide (mean dosage 3." | 1.27 | Mesulergine and pergolide in previously untreated Parkinson's disease. ( Lees, AJ; Stern, GM; Wright, A, 1987) |
| " In nine subjects who completed the trial, the clinical response, occurrence of dyskinesias and of nausea and vomiting, were similar with both treatments, although peak plasma levodopa concentration and levodopa bioavailability were greater on levodopa-domperidone than on levodopa-carbidopa." | 1.27 | Comparison of levodopa with carbidopa, and levodopa with domperidone in Parkinson's disease. ( Langdon, N; Malcolm, PN; Parkes, JD, 1986) |
| "Bromocriptine may be useful in the treatment of hypertension in patients with Parkinson's disease." | 1.27 | Parkinson's disease and hypertension: chronic bromocriptine treatment. ( Chamontin, B; Montastruc, JL; Rascol, A, 1985) |
| "Blood pressure and pulse rate were studied in 20 Parkinsonian patients on no treatment, and during treatment with bromocriptine (mean dosage 148 mg/day) as the sole anti-Parkinsonian therapy." | 1.26 | Bromocriptine in Parkinson's disease: a study of cardiovascular effects. ( Agid, Y; Illas, A; Lhermitte, F; Quinn, N, 1981) |
| "Lisuride is a soluble ergolene derivative with endocrine effects similar to but more potent than those of bromocriptine." | 1.26 | Lisuride in parkinsonism. ( Marsden, CD; Parkes, JD; Schachter, M; Smith, B; Wilson, A, 1981) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 25 (33.78) | 18.7374 |
| 1990's | 19 (25.68) | 18.2507 |
| 2000's | 13 (17.57) | 29.6817 |
| 2010's | 12 (16.22) | 24.3611 |
| 2020's | 5 (6.76) | 2.80 |
| Authors | Studies |
|---|---|
| Nakhlé, G | 1 |
| Brophy, JM | 1 |
| Renoux, C | 2 |
| Khairy, P | 2 |
| Bélisle, P | 1 |
| LeLorier, J | 1 |
| Scorza, FA | 3 |
| de Almeida, AG | 1 |
| Scorza, CA | 3 |
| Finsterer, J | 2 |
| Victorino, DB | 1 |
| Nejm, MB | 1 |
| Guimarães-Marques, MJ | 1 |
| Fiorini, AC | 1 |
| Lastennet, D | 1 |
| Mariani, LL | 1 |
| Rascol, O | 2 |
| Turc, JD | 1 |
| Alfaisal, H | 1 |
| Lapeyre-Mestre, M | 1 |
| Corvol, JC | 1 |
| Tubach, F | 1 |
| Veazie, S | 1 |
| Peterson, K | 1 |
| Ansari, Y | 1 |
| Chung, KA | 1 |
| Gibbons, CH | 1 |
| Raj, SR | 1 |
| Helfand, M | 1 |
| Bacchi, S | 1 |
| Chim, I | 1 |
| Kramer, P | 1 |
| Postuma, RB | 2 |
| Shin, CM | 1 |
| Lee, YJ | 1 |
| Kim, JM | 1 |
| Lee, JY | 1 |
| Kim, KJ | 1 |
| Choi, YJ | 1 |
| Kim, N | 1 |
| Lee, DH | 1 |
| Simeonova, M | 1 |
| de Vries, F | 1 |
| Pouwels, S | 1 |
| Driessen, JHM | 1 |
| Leufkens, HGM | 1 |
| Cadarette, SM | 1 |
| Burden, AM | 1 |
| Lertxundi, U | 1 |
| Domingo-Echaburu, S | 1 |
| Soraluce, A | 1 |
| García, M | 1 |
| Ruiz-Osante, B | 1 |
| Aguirre, C | 1 |
| Buffery, PJ | 1 |
| Strother, RM | 1 |
| Andrzejewski, K | 1 |
| Budzińska, K | 1 |
| Zaremba, M | 1 |
| Kaczyńska, K | 1 |
| Ferraz, HB | 2 |
| Dell'Aniello, S | 1 |
| Marras, C | 1 |
| Bugden, S | 1 |
| Turin, TC | 1 |
| Blais, L | 1 |
| Tamim, H | 1 |
| Evans, C | 1 |
| Steele, R | 1 |
| Dormuth, C | 1 |
| Ernst, P | 1 |
| van Laar, T | 2 |
| Postma, AG | 1 |
| Drent, M | 1 |
| Dewhurst, F | 1 |
| Lee, M | 1 |
| Wood, B | 1 |
| Stiefelhagen, P | 1 |
| Rios Romenets, S | 1 |
| Dauvilliers, Y | 1 |
| Cochen De Cock, V | 1 |
| Carlander, B | 1 |
| Bayard, S | 1 |
| Galatas, C | 1 |
| Wolfson, C | 1 |
| Martínez-Castrillo, JC | 1 |
| Burguera, JA | 1 |
| Morgante, L | 1 |
| Basile, G | 1 |
| Epifanio, A | 1 |
| Spina, E | 1 |
| Antonini, A | 1 |
| Stocchi, F | 3 |
| Di Rosa, E | 1 |
| Martino, G | 1 |
| Marconi, R | 1 |
| La Spina, P | 1 |
| Nicita-Mauro, V | 1 |
| Di Rosa, AE | 1 |
| Grosset, K | 1 |
| Needleman, F | 1 |
| Macphee, G | 1 |
| Grosset, D | 1 |
| Seeman, P | 1 |
| Ko, F | 1 |
| Willeit, M | 1 |
| McCormick, P | 1 |
| Ginovart, N | 1 |
| Brusa, L | 1 |
| Petta, F | 1 |
| Pisani, A | 1 |
| Miano, R | 1 |
| Stanzione, P | 1 |
| Moschella, V | 1 |
| Galati, S | 1 |
| Finazzi Agrò, E | 1 |
| Tumilasci, OR | 1 |
| Cersósimo, MG | 1 |
| Belforte, JE | 1 |
| Micheli, FE | 1 |
| Benarroch, EE | 1 |
| Pazo, JH | 1 |
| Nomoto, M | 2 |
| Nakatsuka, A | 1 |
| Nagai, M | 1 |
| Yabe, H | 1 |
| Moritoyo, T | 1 |
| Moritoyo, H | 1 |
| Nisikawa, N | 1 |
| Schoffer, KL | 1 |
| Henderson, RD | 1 |
| O'Maley, K | 1 |
| O'Sullivan, JD | 1 |
| Müller, T | 2 |
| Muhlack, S | 1 |
| Chamontin, B | 2 |
| Montastruc, JL | 3 |
| Rascol, A | 3 |
| Rinne, UK | 1 |
| Shindler, JS | 2 |
| Finnerty, GT | 1 |
| Towlson, K | 1 |
| Dolan, AL | 1 |
| Davies, CL | 1 |
| Parkes, JD | 7 |
| Bédard, P | 1 |
| Boucher, R | 1 |
| Di Paolo, T | 1 |
| Labrie, F | 1 |
| Quinn, NP | 3 |
| Lang, AE | 3 |
| Thompson, C | 1 |
| Brincat, S | 1 |
| Marsden, CD | 4 |
| Quinn, N | 3 |
| Illas, A | 2 |
| Lhermitte, F | 3 |
| Agid, Y | 3 |
| Schachter, M | 1 |
| Smith, B | 1 |
| Wilson, A | 1 |
| Corsini, GU | 1 |
| Del Zompo, M | 1 |
| Tocco, F | 1 |
| Arca, P | 1 |
| Gessa, GL | 1 |
| Azevedo-Silva, SM | 1 |
| Borges, V | 1 |
| Rocha, MS | 1 |
| Andrade, LA | 1 |
| Calne, DB | 1 |
| Aranda, B | 2 |
| Gervason, CL | 2 |
| Pollak, PR | 1 |
| Limousin, P | 1 |
| Perret, JE | 1 |
| Gálvez-Jiménez, N | 1 |
| Gancher, ST | 2 |
| Woodward, WR | 1 |
| Nutt, JG | 2 |
| Tison, F | 1 |
| Wiart, L | 1 |
| Guatterie, M | 1 |
| Fouillet, N | 1 |
| Lozano, V | 1 |
| Henry, P | 1 |
| Barat, M | 1 |
| Soykan, I | 1 |
| Sarosiek, I | 1 |
| Shifflett, J | 1 |
| Wooten, GF | 1 |
| McCallum, RW | 1 |
| Barone, JA | 1 |
| MacMahon, DG | 1 |
| Zoldan, J | 1 |
| Merims, D | 1 |
| Kuritzky, A | 1 |
| Ziv, I | 1 |
| Melamed, E | 2 |
| Benz, S | 1 |
| Przuntek, H | 1 |
| Albanese, A | 1 |
| Bonuccelli, U | 1 |
| Brefel, C | 1 |
| Chaudhuri, KR | 1 |
| Colosimo, C | 1 |
| Eichhorn, T | 1 |
| Pollak, P | 3 |
| Zappia, M | 1 |
| Sigurdardóttir, GR | 1 |
| Nilsson, C | 1 |
| Odin, P | 1 |
| Grabowski, M | 1 |
| Merello, M | 1 |
| Pirtosek, Z | 1 |
| Bishop, S | 1 |
| Lees, AJ | 3 |
| Clough, CG | 1 |
| Hitchcock, ER | 1 |
| Hughes, RC | 1 |
| Henderson, BT | 1 |
| Kenny, BG | 1 |
| Cramer, P | 1 |
| Adba, MA | 1 |
| Grandas, F | 1 |
| Rodriguez, M | 1 |
| Lera, G | 1 |
| Obeso, JA | 2 |
| Jenner, P | 1 |
| Panegyres, PK | 1 |
| Graham, SJ | 1 |
| Williams, BK | 1 |
| Higgins, BM | 1 |
| Morris, JG | 1 |
| Sabatini, U | 1 |
| Celsis, P | 1 |
| Houin, G | 1 |
| Marc-Vergnes, JP | 1 |
| Day, JP | 1 |
| Pruitt, RE | 1 |
| Capria, A | 1 |
| Attanasio, A | 1 |
| Quatrana, M | 1 |
| Cannata, D | 1 |
| Fioravanti, M | 1 |
| Ruggieri, S | 2 |
| Grandas Perez, FJ | 1 |
| Jenner, PG | 1 |
| Stahl, S | 1 |
| Critchley, P | 2 |
| Stibe, CM | 1 |
| Kempster, PA | 1 |
| Stern, GM | 2 |
| Champion, MC | 2 |
| Brughitta, G | 1 |
| Agnoli, A | 1 |
| Hartnett, M | 1 |
| Yen, M | 1 |
| Mallaret, M | 1 |
| Gaio, JM | 1 |
| Hommel, M | 1 |
| Perret, J | 1 |
| Wright, A | 1 |
| Langdon, N | 2 |
| Malcolm, PN | 1 |
| Leeser, J | 1 |
| Bateman, DN | 1 |
| Luquin, MR | 1 |
| Martínez Lage, JM | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Efficacy of Therapeutic Interventions for Orthostatic Hypotension in Parkinson's Disease and Multiple System Atrophy[NCT00103597] | Phase 1 | 50 participants | Interventional | 2005-01-31 | Completed | ||
| Therapeutic Efficacy of DA-9701 on Gastric Motility in Patients With Parkinson's Disease Evaluated by Magnetic Resonance Imaging: A Randomized Controlled, Double-Blind, Non-Inferiority Trial[NCT03022201] | Phase 4 | 40 participants (Actual) | Interventional | 2013-05-31 | Completed | ||
| Domperidone Use in Parkinson's Disease and Risk of Sudden Cardiac Death[NCT02500108] | 214,962 participants (Actual) | Observational | 2013-05-31 | Completed | |||
| Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy of Continuous Subcutaneous Infusion in Parkinson's Disease Patients With Refractory Visual Hallucinations[NCT02702076] | Phase 2 | 35 participants (Anticipated) | Interventional | 2017-05-31 | Recruiting | ||
| An Investigational New Drug Program for the Use of Domperidone in the Treatment of Refractory Gastroesophageal Reflux Disease and Other Gastrointestinal Motility Disorders[NCT00777439] | 75 participants (Anticipated) | Interventional | 2008-10-31 | Recruiting | |||
| Oral Domperidone for Relief of Gastrointestinal Disorders in Patients Who Failed Standard Therapy[NCT00761254] | 42 participants (Actual) | Interventional | 2008-08-31 | Terminated (stopped due to PI withdrew due to increased responsibilities in clinical department.) | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
11 reviews available for domperidone and Parkinson Disease
| Article | Year |
|---|---|
Fludrocortisone for orthostatic hypotension.
Topics: Bias; Diabetes Mellitus; Domperidone; Dysautonomia, Familial; Fludrocortisone; Humans; Hypotension, | 2021 |
Domperidone for Hypotension in Parkinson's Disease: A Systematic Review.
Topics: Animals; Arrhythmias, Cardiac; Databases, Bibliographic; Death, Sudden, Cardiac; Domperidone; Dopami | 2017 |
Domperidone safety: a mini-review of the science of QT prolongation and clinical implications of recent global regulatory recommendations.
Topics: Antiemetics; Arrhythmias, Cardiac; Brugada Syndrome; Cardiac Conduction System Disease; Death, Sudde | 2015 |
[Proposed alternative to standard apomorphine challenge test].
Topics: Antidotes; Antiparkinson Agents; Apomorphine; Carbidopa; Domperidone; Dopamine Agonists; Dose-Respon | 2012 |
Initiating treatment for idiopathic parkinsonism.
Topics: Antiparkinson Agents; Domperidone; Dopamine Agents; Humans; Parkinson Disease; Time Factors | 1994 |
Domperidone: a peripherally acting dopamine2-receptor antagonist.
Topics: Animals; Data Collection; Diabetes Mellitus; Domperidone; Dopamine Antagonists; Drug Interactions; G | 1999 |
Domperidone: a peripherally acting dopamine2-receptor antagonist.
Topics: Animals; Data Collection; Diabetes Mellitus; Domperidone; Dopamine Antagonists; Drug Interactions; G | 1999 |
Domperidone: a peripherally acting dopamine2-receptor antagonist.
Topics: Animals; Data Collection; Diabetes Mellitus; Domperidone; Dopamine Antagonists; Drug Interactions; G | 1999 |
Domperidone: a peripherally acting dopamine2-receptor antagonist.
Topics: Animals; Data Collection; Diabetes Mellitus; Domperidone; Dopamine Antagonists; Drug Interactions; G | 1999 |
Parkinson's disease: pathological mechanisms and actions of piribedil.
Topics: Aged; Aged, 80 and over; Animals; Brain Chemistry; Callithrix; Domperidone; Humans; Iron; Middle Age | 1992 |
[Use of apomorphine in the treatment of Parkinson's disease].
Topics: Apomorphine; Domperidone; Drug Combinations; Humans; Infusions, Intravenous; Injections, Subcutaneou | 1991 |
Domperidone.
Topics: Colonic Diseases, Functional; Domperidone; Dyspepsia; Esophagitis, Peptic; Gastrointestinal Motility | 1988 |
Domperidone, a new dopamine antagonist.
Topics: Administration, Oral; Adult; Child; Clinical Trials as Topic; Domperidone; Dopamine Antagonists; Dys | 1986 |
Domperidone and Parkinson's disease.
Topics: Antiparkinson Agents; Domperidone; Drug Therapy, Combination; Humans; Parkinson Disease | 1986 |
15 trials available for domperidone and Parkinson Disease
| Article | Year |
|---|---|
DA-9701 on gastric motility in patients with Parkinson's disease: A randomized controlled trial.
Topics: Aged; Antiemetics; Antiparkinson Agents; Domperidone; Double-Blind Method; Female; Gastric Emptying; | 2018 |
Continuous subcutaneous infusion of apomorphine can be used safely in patients with Parkinson's disease and pre-existing visual hallucinations.
Topics: Aged; Analysis of Variance; Antiparkinson Agents; Apomorphine; Domperidone; Female; Hallucinations; | 2010 |
Continuous apomorphine infusion (CAI) and neuropsychiatric disorders in patients with advanced Parkinson's disease: a follow-up of two years.
Topics: Antiemetics; Apomorphine; Brain; Cognition Disorders; Depression; Domperidone; Dopamine Agonists; Dr | 2004 |
Quantitative study of salivary secretion in Parkinson's disease.
Topics: Adult; Aged; Aged, 80 and over; Amylases; Analysis of Variance; Antiparkinson Agents; Case-Control S | 2006 |
Nonpharmacological treatment, fludrocortisone, and domperidone for orthostatic hypotension in Parkinson's disease.
Topics: Aged; Aged, 80 and over; Anti-Inflammatory Agents; Blood Pressure; Cross-Over Studies; Domperidone; | 2007 |
Impact of endurance exercise on levodopa-associated cortisol release and force increase in patients with Parkinson's disease.
Topics: Adult; Aged; Antiemetics; Antiparkinson Agents; Benserazide; Domperidone; Drug Administration Schedu | 2008 |
Bromocriptine and domperidone in the treatment of Parkinson disease.
Topics: Benzimidazoles; Bromocriptine; Domperidone; Female; Humans; Levodopa; Male; Middle Aged; Nausea; Par | 1981 |
Reproducibility of motor effects induced by successive subcutaneous apomorphine injections in Parkinson's disease.
Topics: Aged; Apomorphine; Domperidone; Female; Humans; Injections, Subcutaneous; Male; Middle Aged; Movemen | 1993 |
Apomorphine tolerance in Parkinson's disease: lack of a dose effect.
Topics: Antiparkinson Agents; Apomorphine; Domperidone; Dopamine Antagonists; Dose-Response Relationship, Dr | 1996 |
Effect of chronic oral domperidone therapy on gastrointestinal symptoms and gastric emptying in patients with Parkinson's disease.
Topics: Aged; Antiparkinson Agents; Bromocriptine; Carbidopa; Domperidone; Dopamine Antagonists; Drug Therap | 1997 |
Use of apomorphine in clinical practice.
Topics: Adult; Aged; Aged, 80 and over; Antiemetics; Antiparkinson Agents; Apomorphine; Domperidone; Dopamin | 1999 |
[Apomorphine for treatment of "off-periods" in Parkinson's disease].
Topics: Aged; Antiparkinson Agents; Apomorphine; Domperidone; Female; Humans; Injections, Subcutaneous; Levo | 1999 |
Sublingual apomorphine solution in Parkinson's disease.
Topics: Administration, Oral; Administration, Sublingual; Apomorphine; Domperidone; Drug Therapy, Combinatio | 1991 |
Domperidone, a new dopamine antagonist.
Topics: Administration, Oral; Adult; Child; Clinical Trials as Topic; Domperidone; Dopamine Antagonists; Dys | 1986 |
Blood pressure effects of apomorphine and domperidone in parkinsonism.
Topics: Adult; Aged; Aged, 80 and over; Apomorphine; Blood Pressure; Clinical Trials as Topic; Domperidone; | 1987 |
49 other studies available for domperidone and Parkinson Disease
| Article | Year |
|---|---|
Domperidone increases harmful cardiac events in Parkinson's disease: A Bayesian re-analysis of an observational study.
Topics: Aged; Antiparkinson Agents; Bayes Theorem; Death, Sudden, Cardiac; Domperidone; Female; Humans; Male | 2021 |
Gastrointestinal dysfunctions and sudden death in Parkinson patients: domperidone in FOCUS.
Topics: Death, Sudden; Domperidone; Gastrointestinal Diseases; Humans; Parkinson Disease | 2023 |
Domperidone in Parkinson's disease: a valuable controversy, but unnecessary panic.
Topics: Aged; Cohort Studies; Domperidone; Humans; Parkinson Disease; Potentially Inappropriate Medication L | 2020 |
Evaluation of Prescription Practices of Domperidone in Parkinson's Disease: A Cross Sectional Study Among French Neurologists.
Topics: Adult; Age Factors; Apomorphine; Cross-Sectional Studies; Domperidone; Dopamine Antagonists; Dose-Re | 2020 |
Increased risk of all-cause mortality associated with domperidone use in Parkinson's patients: a population-based cohort study in the UK.
Topics: Aged; Aged, 80 and over; Antiparkinson Agents; Case-Control Studies; Cohort Studies; Domperidone; Do | 2018 |
Domperidone in Parkinson's disease: a perilous arrhythmogenic or the gold standard?
Topics: Administration, Oral; Antiparkinson Agents; Domperidone; Dopamine Antagonists; Dose-Response Relatio | 2013 |
Hypoxic ventilatory response after dopamine D2 receptor blockade in unilateral rat model of Parkinson's disease.
Topics: Adrenergic Agents; Analysis of Variance; Animals; Chromatography, High Pressure Liquid; Disease Mode | 2016 |
Domperidone, Parkinson disease and sudden cardiac death: Mice and men show the way.
Topics: Animals; Death, Sudden, Cardiac; Domperidone; Dopamine Antagonists; Humans; Mice; Models, Animal; Pa | 2016 |
Ventricular tachyarrhythmia and sudden cardiac death with domperidone use in Parkinson's disease.
Topics: Aged; Aged, 80 and over; Antiemetics; Canada; Cohort Studies; Death, Sudden, Cardiac; Domperidone; F | 2016 |
The pragmatic use of apomorphine at the end of life.
Topics: Aged; Antiemetics; Antiparkinson Agents; Apomorphine; Blinking; Deglutition Disorders; Domperidone; | 2009 |
[Prescriptions for gastroparesis].
Topics: Antiemetics; Diabetes Complications; Diagnosis, Differential; Domperidone; Gastroparesis; Humans; Ma | 2010 |
Restless legs syndrome outside the blood-brain barrier--exacerbation by domperidone in Parkinson's disease.
Topics: Aged; Blood-Brain Barrier; Domperidone; Dopamine Antagonists; Female; Humans; Male; Middle Aged; Par | 2013 |
Switching from ergot to nonergot dopamine agonists in Parkinson's disease: a clinical series and five-drug dose conversion table.
Topics: Adult; Adverse Drug Reaction Reporting Systems; Antiparkinson Agents; Benzothiazoles; Bromocriptine; | 2004 |
Antiparkinson concentrations of pramipexole and PHNO occupy dopamine D2(high) and D3(high) receptors.
Topics: Animals; Benzothiazoles; Binding, Competitive; Brain; Cells, Cultured; Cricetinae; Domperidone; Dopa | 2005 |
Central acute D2 stimulation worsens bladder function in patients with mild Parkinson's disease.
Topics: Domperidone; Dopamine Antagonists; Female; Humans; Male; Middle Aged; Parkinson Disease; Severity of | 2006 |
[Inter- and intraindividual pharmacokinetic variations in the treatment of Parkinson's disease].
Topics: Antiparkinson Agents; Area Under Curve; Domperidone; Dopamine Antagonists; Drug Interactions; Humans | 2005 |
[How do we explain the antihypertensive effect of bromocriptine? Clinical and experimental contribution].
Topics: Adrenergic alpha-Antagonists; Aged; Animals; Antihypertensive Agents; Bromocriptine; Dogs; Domperido | 1984 |
Dopamine agonists in the treatment of Parkinson's disease.
Topics: Blood Pressure; Bromocriptine; Disability Evaluation; Domperidone; Dopamine; Ergolines; Follow-Up St | 1983 |
Domperidone and levodopa in Parkinson's disease.
Topics: Aged; Blood Pressure; Domperidone; Drug Interactions; Female; Humans; Levodopa; Male; Middle Aged; P | 1984 |
Interaction between estradiol, prolactin, and striatal dopaminergic mechanisms.
Topics: Animals; Corpus Striatum; Domperidone; Dopamine; Estradiol; Female; Haloperidol; Macaca fascicularis | 1984 |
Pergolide in the treatment of Parkinson's disease.
Topics: Antiparkinson Agents; Domperidone; Ergolines; Humans; Levodopa; Mental Disorders; Parkinson Disease; | 1984 |
Lisuride in parkinsonism.
Topics: Administration, Oral; Aged; Benzimidazoles; Chorea; Domperidone; Dose-Response Relationship, Drug; D | 1981 |
[Long-term results of treatment of Parkinson's disease with bromocriptine and domperidone (author's transl)].
Topics: Aged; Aromatic Amino Acid Decarboxylase Inhibitors; Benzimidazoles; Bromocriptine; Domperidone; Drug | 1981 |
Bromocriptine in Parkinson's disease: a study of cardiovascular effects.
Topics: Benzimidazoles; Blood Pressure; Bromocriptine; Domperidone; Humans; Parkinson Disease; Piperidines; | 1981 |
Drugs acting on dopamine receptors: usefulness of a peripheral blocker in Parkinson's disease.
Topics: Apomorphine; Behavior; Benzimidazoles; Domperidone; Double-Blind Method; Drug Interactions; Female; | 1980 |
[Apomorphine: an alternative in the control of motor fluctuations in Parkinson's disease].
Topics: Antiparkinson Agents; Apomorphine; Domperidone; Dopamine Antagonists; Drug Therapy, Combination; Fem | 1995 |
[Vesical sphincter disorders in Parkinson disease].
Topics: Aged; Aged, 80 and over; Apomorphine; Domperidone; Female; Humans; Male; Middle Aged; Parkinson Dise | 1993 |
Perioperative problems in Parkinson's disease and their management: apomorphine with rectal domperidone.
Topics: Administration, Rectal; Aged; Apomorphine; Domperidone; Female; Humans; Male; Middle Aged; Parkinson | 1996 |
Effects of central dopaminergic stimulation by apomorphine on swallowing disorders in Parkinson's disease.
Topics: Aged; Antiparkinson Agents; Apomorphine; Brain; Deglutition Disorders; Domperidone; Dopamine Antagon | 1996 |
Choice reaction time after levodopa challenge in parkinsonian patients.
Topics: Adult; Aged; Domperidone; Drug Interactions; Female; Humans; Levodopa; Male; Middle Aged; Movement; | 2000 |
Consensus statement on the role of acute dopaminergic challenge in Parkinson's disease.
Topics: Apomorphine; Corpus Striatum; Decision Making; Domperidone; Dopamine Agonists; Dopamine Antagonists; | 2001 |
Acute orthostatic hypotension when starting dopamine agonist therapy in parkinson disease: the role of domperidone therapy.
Topics: Acute Disease; Domperidone; Dopamine Agonists; Dopamine Antagonists; Humans; Hypotension, Orthostati | 2001 |
Cardiovascular effects of domperidone in patients with Parkinson's disease treated with apomorphine.
Topics: Aged; Antiparkinson Agents; Apomorphine; Blood Pressure; Blood Pressure Monitoring, Ambulatory; Card | 2001 |
Cardiovascular reflexes in Parkinson's disease: effect of domperidone and apomorphine.
Topics: Aged; Apomorphine; Blood Pressure; Domperidone; Female; Heart Rate; Humans; Male; Middle Aged; Parki | 1992 |
Brain implants in man do not break down the blood-brain barrier to dopamine and domperidone.
Topics: Adult; Aged; Apomorphine; Blood-Brain Barrier; Brain; Domperidone; Dopamine; Drug Implants; Female; | 1992 |
[Effect of apomorphine on the bladder of parkinsonian patients].
Topics: Aged; Aged, 80 and over; Apomorphine; Domperidone; Drug Therapy, Combination; Female; Humans; Inject | 1992 |
Differences in the motor response to apomorphine between untreated and fluctuating patients with Parkinson's disease.
Topics: Adult; Aged; Apomorphine; Carbidopa; Domperidone; Humans; Levodopa; Middle Aged; Parkinson Disease; | 1992 |
Subcutaneous apomorphine increases regional cerebral blood flow in parkinsonian patients via peripheral mechanisms.
Topics: Aged; Apomorphine; Blood Pressure; Cerebrovascular Circulation; Domperidone; Female; Humans; Injecti | 1991 |
Diabetic gastroparesis in a patient with Parkinson's disease: effective treatment with domperidone.
Topics: Diabetic Neuropathies; Domperidone; Female; Humans; Middle Aged; Parkinson Disease; Stomach Diseases | 1989 |
Cardiovascular effects of lisuride continuous intravenous infusion in fluctuating Parkinson's disease.
Topics: Adult; Blood Pressure; Domperidone; Drug Therapy, Combination; Electrocardiography; Ergolines; Femal | 1989 |
(+)-4-Propyl-9-hydroxynaphthoxazine in Parkinson's disease.
Topics: Animals; Callithrix; Carbidopa; Domperidone; Dose-Response Relationship, Drug; Drug Combinations; Dr | 1986 |
Subcutaneous apomorphine in parkinsonian on-off oscillations.
Topics: Adult; Aged; Apomorphine; Domperidone; Drug Evaluation; Drug Therapy, Combination; Female; Humans; I | 1988 |
Problems in daily motor performances in Parkinson's disease: the continuous dopaminergic stimulation.
Topics: Administration, Oral; Adult; Aged; Carbidopa; Domperidone; Ergolines; Female; Humans; Infusions, Int | 1986 |
Mesulergine and pergolide in previously untreated Parkinson's disease.
Topics: Aged; Antiparkinson Agents; Domperidone; Ergolines; Female; Humans; Male; Parkinson Disease; Pergoli | 1987 |
Comparison of levodopa with carbidopa, and levodopa with domperidone in Parkinson's disease.
Topics: Adult; Aged; Benserazide; Carbidopa; Domperidone; Drug Therapy, Combination; Female; Humans; Levodop | 1986 |
Domperidone.
Topics: Domperidone; Humans; Nausea; Parkinson Disease | 1985 |
Domperidone.
Topics: Domperidone; Humans; Parkinson Disease; Vomiting | 1985 |
Intravenous lisuride corrects oscillations of motor performance in Parkinson's disease.
Topics: Adult; Aged; Domperidone; Drug Therapy, Combination; Dyskinesia, Drug-Induced; Ergolines; Female; Hu | 1986 |
Parkinson's disease and hypertension: chronic bromocriptine treatment.
Topics: Aged; Bromocriptine; Domperidone; Female; Humans; Hypertension; Male; Parkinson Disease | 1985 |